H.R. 5391 · 118th Congress

Protecting Patient Access to Cancer and Complex Therapies Act

Introduced on Sep 12, 2023 by Michael C. Burgess (R-TX-26). 4 cosponsors, all from the sponsor's party. Latest action (Dec 17, 2024): Referred to the Subcommittee on Health.

Stage
Introduced
Introduced
Sep 12, 2023
Cosponsors
4
0 from the other party
Policy area
Health
Open in the Congress explorerCongress.govAlert me

Progress

The furthest stage the measure reached. Simple and concurrent resolutions do not go to the President.

  1. Introduced
  2. 2Reported by committee
  3. 3Passed one chamber
  4. 4Passed both chambers
  5. 5Sent to the President
  6. 6Became law

Official title

To amend title XVIII of the Social Security Act to provide for a rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation.

Subjects

  • Civil actions and liability
  • Health care costs and insurance
  • Manufacturing
  • Prescription drugs

Summary

The Congressional Research Service has not summarized this measure yet.

Sponsor and cosponsors

Cosponsors by party as of the day they signed on. Original cosponsors signed on the day of introduction.

Michael C. BurgessR-TX-26Sponsor

Republicans · 4

Roll calls

Recorded votes on the measure. Most measures move by voice vote or unanimous consent, which record no individual positions.

No recorded roll call on this measure: it moved by voice vote or unanimous consent, or has not reached the floor.

History

Every action as published, oldest first. Roll calls link to how each member voted.

  1. Sep 12, 2023Introduced in House
  2. Sep 12, 2023Introduced in House
  3. Sep 12, 2023 · HouseReferred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  4. Sep 12, 2023 · HouseReferred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  5. Sep 15, 2023 · HouseReferred to the Subcommittee on Health.
  6. Dec 17, 2024 · HouseReferred to the Subcommittee on Health.

Committees

Committees and subcommittees the measure was referred to.

Agencies in its committees' jurisdiction

Analisa's mapping of committee jurisdiction to federal agencies; the bill may touch others, or none of these.

Who lobbied on it

Organizations whose lobbying reports (LD-2) name this measure. Spending is what they reported for those quarters on all issues, not on this measure alone.

  1. HealthCare Institute of New Jersey11 reports
    $557.4K reported (all issues)
  2. Digestive Health Physicians Association10 reports
    $590K reported (all issues)
  3. Infusion Providers Alliance10 reports
    $135K reported (all issues)
  4. AMGEN INC.9 reports
    $11.6M reported (all issues)Federal contractor: AMGEN INC.AI match · 99%
  5. PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA9 reports
    $37.4M reported (all issues)
  6. ASSOCIATION OF CANCER CARE CENTERS (FKA ASSOCIATION OF COMMUNITY CANCER CENTERS)7 reports
    $170K reported (all issues)
  7. Cencora fka AmerisourceBergen Corporation6 reports
    $300K reported (all issues)
  8. AMERICAN COLLEGE OF RHEUMATOLOGY5 reports
    $460K reported (all issues)
  9. ASSOCIATION FOR CLINICAL ONCOLOGY5 reports
    $1.1M reported (all issues)
  10. GENENTECH INC.5 reports
    Federal contractor: GENENTECH USA, INC$939.6K in contracts, FY2026AI match · 100%
  11. GSK (fka GLAXOSMITHKLINE INC.)5 reports
    $6.3M reported (all issues)
  12. Large Urology Group Practice Association5 reports
    $450K reported (all issues)
  13. Large Urology Group Practice Association (LUGPA)5 reports
    $300K reported (all issues)
  14. BIOTECHNOLOGY INNOVATION ORGANIZATION3 reports
    $6.2M reported (all issues)
  15. Daiichi Sankyo, Inc.3 reports
    $1.1M reported (all issues)Federal contractor: DAIICHI SANKYO, INC$205.9K in contracts, FY2026AI match · 100%
  16. GILEAD SCIENCES, INC.3 reports
    Federal contractor: GILEAD SCIENCES INCAI match · 100%
  17. NOVARTIS CORPORATION2 reports
    $5.3M reported (all issues)Federal contractor: NOVARTIS PHARMACEUTICALS CORPORATION$36.2M in contracts, FY2026AI match · 100%
  18. TAKEDA PHARMACEUTICALS AMERICA, INC.1 report
    $510K reported (all issues)Federal contractor: TAKEDA PHARMACEUTICALS AMERICA, INC.$1.6M in contracts, FY2026AI match · 100%

Reports filed in 2023, 2024, 2025, 2026.

Sources and method

Every figure on this page traces to these records.

  • Bill status: bills and resolutions, sponsors, actions, subjects and CRS summaries (U.S. Government Publishing Office (GovInfo), from Congress.gov (Library of Congress))GovInfo Bill Status bulk data (Congress.gov; summaries by the Congressional Research Service) · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Members of Congress, their terms, committees and identifiers (The @unitedstates project (from the Biographical Directory of the U.S. Congress, the House and the Senate))unitedstates/congress-legislators: legislators, committees and current committee membership · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: CC0 1.0 (public domain dedication)
  • House roll-call votes (Office of the Clerk, U.S. House of Representatives)Office of the Clerk, U.S. House of Representatives, roll-call vote records · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Senate roll-call votes and DW-NOMINATE scores (Voteview (UCLA Department of Political Science))Lewis, Jeffrey B., Keith Poole, Howard Rosenthal, Adam Boche, Aaron Rudkin, and Luke Sonnet (2026). Voteview: Congressional Roll-Call Votes Database. https://voteview.com/ · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: Free to use with the required citation
  • Lobbying disclosures (LD-1 registrations, LD-2 quarterly reports, LD-203 contribution reports) (Clerk of the U.S. House of Representatives)Clerk of the House, Lobbying Disclosure Act filings (organizations only; lobbyists' names are not loaded) · data current to Oct 6, 2026 · loaded Oct 6, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Positions are shown only where a roll call recorded them; voice votes and unanimous consent record none.
  • Money and votes are shown side by side; neither explains the other.